Nov 4, 2019 • 4:10pm EST

Synthetic Biologics Reports Third Quarter 2019 Operational Highlights and Financial Results

-- Enrollment is Ongoing in Phase 2b Investigator-Sponsored Clinical Study of SYN-010, for the Treatment of IBS-C -- -- Conference Call Today, November 4, 2019, at 4:30 p.m. (EST) -- ROCKVILLE, Md., Nov. 4, 2019 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today provided an operational update and reported financial results for the three and nine months ended September 30, 2019. ...